Condensed

See the latest coronavirus and vaccine informationLearn about the Lancaster General Hospital Emergency Department expansion and related traffic changes.

On May 1, the U.S. Food and Drug Administration approved CAR-T cell therapy developed by Penn Medicine for use in the most common form of non-Hodgkin’s lymphoma. This breakthrough means that more patients will be able to receive the potentially life-saving treatment.

Click here to read more.
 



Staff at the Ann B. Barshinger Cancer Institute gathered May 2 to celebrate a second FDA approval of the Penn Medicine-developed CAR-T cell therapy, this time for adult patients with non-Hodgkin’s lymphoma. 


 

Share This Page: